Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company whose business model is predicated on the development of novel drug candidates. As a pharmaceutical research entity, its drug discovery and development pipeline inherently relies on animal testing to satisfy regulatory requirements for safety and efficacy prior to human clinical trials. This standard industry practice involves the commercial exploitation of animals in laboratory settings, which falls under the broad exclusion category for animal exploitation.

The company’s primary drug candidate, lenabasum, progressed through preclinical studies that required animal models. A 2024 study published in the journal *Drug and Alcohol Dependence*, which evaluated the abuse potential of lenabasum, involved human participants (n=56), but such clinical-stage research is built upon foundational animal data. As a company with no marketed products and whose value is derived entirely from its research pipeline, Corbus’s operations are fundamentally dependent on animal testing.